Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Neuroblastoma: Activated telomerase is responsible for aggressive course

No. 45a | 15/10/2015 | by Koh

Neuroblastoma, a tumor of the peripheral nervous system, is one of the most common forms of cancer in children. In some patients, these tumors regress completely without any treatment, whereas in others, even highly intensive treatment fails to halt the disease. Scientists from Cologne University and from the German Cancer Research Center (DKFZ) in Heidelberg have now elucidated the genetic causes that underlie these variations in the clinical course of the disease. They discovered that one of the genes encoding a subunit of the telomerase enzyme is highly activated in the most aggressive tumors. This enzyme extends the ends of chromosomes, thus making cells virtually immortal. The researchers have now published their results in the journal “Nature”.

© Dr. Larissa Savelyeva, DKFZ

Scientists from the Children’s Hospital at Cologne University and the Institute of Translational Genomics at the University of Cologne, in collaboration with researchers from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) in Heidelberg, analyzed genetic information from 217 neuroblastomas.

In about one third of all high-risk neuroblastomas, the researchers discovered various genomic changes in chromosome 5, which all led to higher-than-normal activity of a gene called TERT.

TERT encodes the genetic information for one of two subunits of an enzyme called telomerase, which plays a major role in stabilizing the chromosome ends, or telomeres. Telomeres are often referred to as the cell’s molecular clocks: In most of the body's cells, telomeres shorten every time a cell divides. When the telomeres reach a critical length, the cell stops dividing and often dies. In stem cells and most cancer cells, however, telomeres are maintained by the telomerase, thus making the cells virtually “immortal”.

In the current study, the scientists from Cologne and Heidelberg discovered that a previously unknown genomic change in this gene leads to an activation of telomerase that is only found in aggressively growing neuroblastomas. Patients whose cells exhibit this mutation have poorer chances of being cured.

In another share of high-risk neuroblastoma cases, the investigators additionally discovered an amplification of the MYCN oncogene, which has an activating effect on telomerase. And in another third of aggressive tumor cases, yet another mechanism is in place that stabilizes the chromosome ends. This means that the vast majority of high-risk neuroblastomas use multiple biological pathways to prevent that their chromosome ends from shortening below the critical length. In contrast, these mechanisms were not detected in neuroblastomas that spontaneously regress.

“Our results show that the biological behavior of neuroblastoma cells depends largely on whether or not telomeres are being lengthened,” says Prof. Dr. Matthias Fischer. ”If this is the case, the tumors grow aggressively. Without telomere lengthening, the tumor regresses spontaneously.” Fischer is one of the leaders of the study, which is supported by German Cancer Aid (Deutsche Krebshilfe) and the Federal Ministry of Education and Research (BMBF).

The mutation affects a novel mechanism by which TERT (and, thus, telomerase) is activated in neuroblastoma cells. Up until now, scientists have presumed that a gene amplification or mutations in control regions result in moderate telomerase activation in cancer cells. However, the genome analyses revealed a completely different situation: “We found large-scale rearrangements in the genetic material of aggressive neuroblastomas,” says Associate Professor (PD) Frank Westermann, who leads the study at the DKFZ. “These place the TERT gene very close to strong tissue-specific genetic enhancers where its transcription rate reaches up to 90 times that of normal cells.”

Westermann’s co-workers Dr. Daniel Dreidax and Moritz Gartlgruber used a specially developed method to detect the genetic enhancer elements in the tumor genome.

“The study findings fundamentally change our understanding of neuroblastoma and might have a major impact on diagnosis and treatment in neuroblastoma patients,” says Fischer. “For example, the detection of active telomere lengthening in the tumor might be used as a means of precisely predicting the clinical course in an individual patient and to adjust his or her treatment accordingly.”

In addition, developing drugs that inhibit telomerase or its subunit TERT might offer a promising new approach to treatment for patients whose tumors exhibit activated telomerase.

Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, Krämer A, Roncaioli JL, Sand F, Heuckmann J, Ikram F, Schmidt R, Ackermann S, Engesser A, Kahlert Y, Vogel W, Altmüller J, Nürnberg P, Thierry-Mieg J, Thierry-Mieg D, Mariappan A, Heynck S, Mariotti E, Henrich KO, Glöckner C, Bosco G, Leuschner I, Schweiger MR, Savelyeva L, Watkins SC, Shao C, Bell E, Höfer T, Achter V, Lang U, Theissen J, Volland R, Saadati M, Eggert A, de Wilde B, Berthold F, Peng Z, Zhao C, Shi L, Ortmann M, Büttner R, Perner S, Hero B, Schramm A, Schulte JH, Herrmann C, O’Sullivan RJ, Westermann F, Thomas RK, Fischer M. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 2015; DOI: 10.1038/nature14980

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS